Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Raltegravir 400 mg

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2028 · 672 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Raltegravir 400 mg (ATC-Code nach WHO: J05AJ01)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase; actual demand unknown and dependent on prescriptions, patient numbers, and pharmacy behavior.

Buyer may terminate the Open-House process early if exclusive rebate agreements are concluded, ending existing contract...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Supply of Raltegravir 400 mg tablets
  • Participation in a non-exclusive drug discount agreement with AOK PLUS
Afficher le résumé complet

Non-exclusive drug discount agreement for Raltegravir 400 mg (ATC J05AJ01) under an Open-House model. Any qualified pharmaceutical company can enter into a rebate contract with AOK PLUS. No guaranteed volumes, no exclusive rights, and no competitive award process. The agreement runs until June 30, 2028, with periodic submission deadlines. The contract value is not disclosed.

Risques

No minimum purchase; actual demand unknown and dependent on prescriptions, patient numbers, and pharmacy behavior.

Buyer may terminate the Open-House process early if exclusive rebate agreements are concluded, ending existing contract...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical enterprise as defined in §4 Abs. 18 AMG
  • Must be established in Germany, EU, or EEA

Eligibility

  • Submit self-declaration on absence of exclusion grounds (GWB §§123,124)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; this is an Open-House model where any qualified participant can join.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Raltegravir 400 mg

Open to all interested pharmaceutical companies meeting participation requirements. The contract is a rebate agreement under §130a Abs. 8 SGB V. No minimum order quantity; volume depends on prescriptions and demand.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; this is an Open-House model where any qualified participant can join.

Date limite

Deadline Jun 30, 2028

Détails de la procédure

Date de publication
07 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
238743-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30